Company Overview. October 2018
|
|
- Luke McKinney
- 5 years ago
- Views:
Transcription
1 Company Overview October
2 Disclaimer This presentation, the information contained herein and the materials accompanying it (collectively, this Presentation ) does not purport to contain all of the information that may be required by the recipients (the Recipients ) to evaluate Gamida Cell Ltd. ( we or the Company ), and the Recipients rely on their own independent analysis and should seek their own legal, accounting and other relevant professional advice to assess the accuracy and completeness of the Presentation. Acceptance of this Presentation further constitutes your acknowledgement and agreement that none of the Company, the Company s investors, and their respective affiliates and their and their affiliates directors, officers, employees, partners, shareholders, controlling persons, agents or advisers (collectively, their respective Representatives ) (i) makes any express or implied representation or warranty as to, or in relation to, the accuracy or completeness of the information contained in the Presentation, errors therein or omissions therefrom or any other written or oral communication transmitted to any interested party in the course of its evaluation of the Company or (ii) shall have any liability to the Recipients or their respective Representatives relating to or arising from the information contained in the Presentation, errors therein or omissions therefrom, or any other written or oral communication transmitted to any interested party in the course of its evaluation of the Company. This Presentation has been prepared by the Company for use during a testing-the-waters meeting pursuant to Section 5(d) of the U.S. Securities Act of 1933, as amended (the Securities Act ) solely for informational purposes and is not an offer to buy or sell, or a solicitation of an offer to buy or sell, any security or instrument of the Company, or to participate in any investment activity or trading strategy, nor may it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever, in the United States or anywhere else. You further represent to us that you are a qualified institutional buyer as such term is defined in Rule 144A under the Securities Act or an institutional accredited investor as such term is defined in Rule 501 (a)(1), (2), (3) or (7) under the Securities Act, whether you are in the United States or outside of the United States. The Company is not making any offer of its securities at this time, and cannot accept orders for any securities at this time. This Presentation does not constitute an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company in any jurisdiction or an inducement to enter into investment activity, nor may it or any part of it form the basis of or be relied upon in connection with any contract or commitment whatsoever. Specifically, this Presentation does not constitute a prospectus within the meaning of the Securities Act. This Presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company. No securities of the Company may be sold in the United States without registration with the U.S. Securities and Exchange Commission (the SEC ) or an exemption from such registration. Any public offer of securities would be made pursuant to an effective registration statement and prospectus prepared by the Company that would contain material information not contained herein and to which any prospective purchasers are referred. Any offering of the securities of the Company to be made in the United States will be made solely on the basis of the information contained in the statutory prospectus included in a registration statement to be filed by the Company with the SEC. The prospectus will contain detailed information about the Company and its management as well as the financial statements of the Company and risks and uncertainties associated with our business and industry. In the event of any such offering, this Presentation shall be deemed superseded, amended and supplemented in its entirety by such prospectus. If you invest in any securities of the Company, you should read such statutory prospectus and other documents that the Company may file with the SEC. We can provide you with a copy of the statutory prospectus once it is available. These materials are qualified in their entirety by reference to the detailed information to be provided in in the statutory prospectus. In addition, this Presentation includes certain projections and forward-looking statements as of the date of this Presentation provided by the Company. The information in this Presentation is current only as of its date and may have changed since that date. These projections and forward-looking statements include, but are not limited to, those regarding the Company s future financial position and results of operations, the Company s commercialization, marketing and manufacturing capabilities and strategy, the Company s intellectual property position, regulatory matters, market size and opportunity and the Company s estimates regarding expenses, future revenues, capital requirements and needs for additional financing. These projections and forward-looking statements are based on the beliefs of the Company s management as well as assumptions made and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about the Company and its subsidiaries and investments, including, among other things, the development of its business, trends in the industry, the legal and regulatory framework for the industry and future expenditures. In light of these risks, uncertainties, contingencies and assumptions, the events or circumstances referred to in the forward-looking statements may not occur. None of the future projections, expectations, estimates or prospects in this presentation should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in the presentation. The actual results may vary from the anticipated results and the variations may be material. 2
3 Investment Highlights NiCord : Product candidate for bone marrow transplant with curative potential Phase 3 registration study in patients with hematologic malignancies ongoing Received FDA Breakthrough Therapy Designation and Orphan Designation from FDA and EMA Preparing for potential U.S. launch Proven, proprietary nicotinamide (NAM)-based cell expansion technology Phase 1/2 study of NiCord in severe aplastic anemia ongoing Phase 1 study of NAM-NK in non-hodgkin lymphoma and multiple myeloma Wholly-owned clinical pipeline sets the stage for multiple milestones through 2020 Experienced executive team; recently established U.S. headquarters 3
4 Gamida Cell Has Worldwide Rights to Its Clinical Pipeline PRODUCT PRECLINICAL PHASE 1/2 PHASE 3 MILESTONES High-Risk Hematologic Malignancies Top-line data 1H20 NiCord Severe Aplastic Anemia* Preliminary data 2019 NAM-NK Hematologic Malignancies Additional data 1H19 4 *The Aplastic Anemia Investigational New Drug (IND) application is currently filed with the FDA under the brand name, CordIn, which is the same investigational development candidate as NiCord.
5 The Gamida Cell Executive Team Has Substantial Experience Julian Adams, Ph.D. Chairman & Chief Executive Officer Josh Hamermesh Chief Business Officer Shai Lankry Chief Financial Officer Tzvi Palash Chief Operating Officer Tony Peled Chief Scientific Officer Ronit Simantov, M.D. Chief Medical Officer 5
6 NiCord Hematologic Malignancies 6
7 Bone Marrow Transplant May Be Curative in Hematologic Malignancies Lymph nodes Bone marrow Treatment Complete Remission Relapse or refractory Eligible for bone marrow transplant Blood and lymph node cancers (e.g., AML, ALL, MDS, CML, HL, NHL)* Allogeneic stem cell transplant (HSCT) is an effective treatment for patients with life-threatening blood cancers >70% of allogeneic HSCT in the US are performed in patients with acute leukemia or myelodysplastic syndrome 1 7 *AML: acute myelogeneous leukemia; ALL: acute lymphoblastic leukemia; MDS: myelodysplastic syndrome; CML: Chronic myelogenous leukemia; HL: Hodgkin lymphoma; NHL: non-hodgkin lymphoma. 1 D'Souza A, Fretham C. Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): Center for International Blood and Marrow Transplant Research (CIBMTR) 2017 Summary Slides (the CIBMTR Slides )
8 Allogeneic Bone Marrow Transplantation Must Be Improved Conditioning Stem Cell Infusion Engraftment Day Medical Need Patients have a high risk of infections and other complications such as graft vs host disease Many patients never get to transplant or have a significant wait to get a match 8
9 HSCT Candidate Patient Segmentation Not matched / not referred 40% Matched unrelated donor 25% Haploidentical donor 10% Addressable by NiCord Umbilical cord blood 5% Family-related matched donor 20% 9 Not matched / not referred based on: Besse K, et al. Estimating Demand and Unmet Need for Allogeneic Hematopoietic Cell Transplantation in the United States Using Geographic Information Systems. Journal of Oncology Practice Volume 11 Issue 2 March 2015 (the 2015 Besse Paper ) and The Nemetz Group LLC Crowdsourced Survey of US Allo-HSCT Transplanters April 2018 (the Nemetz April Survey ). All other segments: CIBMTR Slides.
10 Nicotinamide (NAM) Technology: Mechanism of Action NAM causes metabolic reprogramming, leading to cell proliferation while preserving stem cells O NH 2 N NAM Preserved Gene Expression Noncultured Cultured w/o NAM Cultured +NAM 10
11 NiCord Is a Pharmaceutical-Grade, Universal Bone Marrow Transplant Product Manufacturing and Treatment Process For NiCord Cord Blood Unit (CBU) NiCord NiCord Infusion CBU selected by physician from public cord blood bank Stem cells cultured for 3 weeks using proprietary NAM technology Uncultured fraction 11
12 Phase 1/2 Study of NiCord in Patients with Hematologic Malignancies Age Hematologic Malignancies AML MDS ALL CML Lymphoma Eligible for Transplant No matched donor 13 sites: U.S., EU, Asia N=36 Myeloablative Conditioning Day Transplantation with NiCord Primary endpoint: Neutrophil engraftment Follow-up Secondary endpoints: Platelet engraftment, acute GvHD, chronic GvHD, infections, hospitalization, non-relapse mortality, overall survival, disease-free survival 12 Clinicaltrials.gov identifier NCT
13 Cumulative Incidence of Neutrophil Engraftment Rapid Neutrophil Engraftment with NiCord ~50% reduction in time to engraftment is associated with clinical benefit 94% of patients engrafted 85% of patients engrafted Median days to engraftment) NiCord: 11 days (95%CI: 9-13d) CIBMTR Cohort: 21 days (95%CI: 20-23d) p<0.001 NiCord CIBMTR Cohort Days Post Transplant 13 Horwitz et al., ASH Note: CIBMTR registry data of 146 patients who received myeloablative conditioning and unmanipulated cord blood transplantation.
14 Incidence of Platelet Engraftment Cumulative Incidence of Platelet Engraftment Significantly Improved Platelet Engraftment with NiCord 81% of patients engrafted 63% of patients engrafted Days to engraftment (median) NiCord: 34 days (95%CI: 32-42d) CIBMTR Cohort: 46 days (95%CI: 42-50d) p< Days Post Transplant NiCord CIBMTR Cohort 14 Horwitz et al., ASH Note: CIBMTR registry data of 146 patients who received myeloablative conditioning and unmanipulated cord blood transplantation.
15 Mean Infections per 100 patient-days Rapid Engraftment Is Associated with Fewer Infections and Shorter Hospitalizations Days Alive and out of Hospital by Day 100 Infection Hospitalization NiCord Standard Cord Total Infections Bacterial Infections 15 Anand et al. BBMT 23:1151-7, 2017.
16 Phase 1/2 NiCord Study: Secondary Endpoint Results Chimerism agvhd: Grade III-IV at 100 days Full donor (>95%): 97% Mixed chimerism: 3% 11% cgvhd: Moderate-Severe at 1 year 10% Number of days of primary hospitalization 19d Number of days alive and out of hospital by Day 100 (median) 73d Median follow-up 14 months (range 5-37m) 16 Horwitz et al., ASH 2017.
17 Cells/µl (median) Phase 1/2 NiCord Study: NiCord Recipients Experienced Rapid and Robust Immune Reconstitution (IR) Following Transplantation NK, B-cells and monocyte reconstitution faster than transplant with unmanipulated cord blood (CB) and bone marrow (BM) At 100 days post transplantation with NiCord, CD4+ reconstitution is at least as fast as transplant with unmanipulated CB and BM in young adolescents Day 100 NiCord Unmanipulated Dual Cord Optimal comparison of IR in randomized Phase 3 study of NiCord is underway CD4+ CD8+ B-cells NK-cells 17 Horwitz et al., ASH 2017; Nierkens et al., EBMT 2018; Barker et al: Brit J Haem 2015.
18 NiCord Phase 1/2 Case Study: Patient #1 63 y/o retired male and avid golfer with acute myeloid leukemia, first complete remission No matched donors in National Marrow Donor Program (NMDP) registry Neutrophil recovery on Day 14 and discharged from hospital early on Day 16 Grade II GvHD, resolved with short course prednisone Disease free for 7 years and returns to Duke for annual visits 18
19 NiCord Phase 1/2 Study: Key Takeaways Results demonstrated potential of NiCord to be an effective transplantation solution for patients with high-risk blood cancers Median time to neutrophil engraftment: 11 days (vs. 21 days for CIBMTR control) Significant reduction in rate and severity of infections as well as significantly shorter hospital stays Acceptable safety profile, with low incidence of acute and chronic GvHD FDA Breakthrough Therapy Designation 19
20 Phase 3 Registration Study of NiCord for Allogeneic Transplantation in 120 Patients with Hematologic Malignancies 120 patients with hematologic malignancies Eligible for allogeneic bone marrow transplantation No suitable donor R NiCord (60 patients) Standard Cord Blood (60 patients) Primary endpoint: Time to neutrophil engraftment Secondary endpoints: Platelet engraftment, acute GvHD, chronic GvHD, infections, hospitalization, non-relapse mortality, overall survival, disease-free survival 15 sites initiated in the U.S., EU and Asia; Expect to open additional sites Expected enrollment completion: 2H19; Topline data anticipated 1H20 Concurrent collaboration with CIBMTR to collect real world outcomes in patients following bone marrow transplantation 20 Clinicaltrials.gov identifier NCT
21 NiCord Designed to Provide Significant Benefits to Patients, Physicians, Providers and Payers Patients and Physicians Better clinical outcomes Rapid hematopoietic recovery Reduced morbidity Providers (Hospitals) Shorter hospital stay by ~20 days Improved efficiency in beds utilization, allows more patients to receive treatment Decrease in resource utilization Primarily a commercial insurance patient population $ Payers One time infusion with improved and potentially durable outcomes for their beneficiaries Potential decrease in total cost of care 21
22 Intellectual Property and Exclusivity Exclusivity protection due to trade secrets NiCord patent coverage with NAM technology Orphan drug designation in the U.S and EU resulting in exclusivity - 12 years in U.S years in EU Orphan drug designation 22
23 NiCord Advanced Hematologic Disorders 23
24 NiCord Potential in Severe Aplastic Anemia Bone Marrow Transplant Is the Only Known Cure for Severe Aplastic Anemia Americans are diagnosed with aplastic anemia each year 1 Cohort 1 Patients with severe aplastic anemia (N = 3) Reduced-intensity conditioning NiCord + haploidentical stem cell graft Cohort 2 Patients with severe aplastic anemia (N = 23) Reduced-intensity conditioning NiCord Cohort 1 ongoing Next steps: Evaluate outcomes after first 3 patients; expansion to additional study sites Registration strategy: Single-arm study following FDA discussion 24 1 Aplastic Anemia and MDS International Foundation: Clinicaltrials.gov identifier NCT
25 Natural Killer (NK) Cell Development Candidate Harnessing Innate Immunity in Cancer 25
26 NAM-NK Immunotherapy NK cells infusion is a promising immune therapy for cancer: No antigen presentation required No HLA-matching required Low risk of inducing GvHD Synergy with antibodies Immune system recruitment NAM Expansion of Natural NK Cells NAM NAM-NK + Tumor-Specific Antibodies Expansion is necessary to obtain clinically meaningful doses 26
27 NAM-NK Cell Immunotherapy Program High Affinity Antibodies Bind NK Cells and Home to Lymphoma Cells Killing (%) 40 Antibody dependent cellular cytotoxicity (ADCC) 30 Ab 20 ADCC Tumor cells 10 Tumor cells 0 NK NK + Rituximab Rituximab NK cells 27 Brachya et al., ASH 2017.
28 Phase 1 Study of NAM-NK Cells in Patients with Multiple Myeloma or Non-Hodgkin Lymphoma Patients with multiple myeloma or Non-Hodgkin lymphoma (N = 24) Fludarabine/cyclophosphamide Lymphodepleting preparative regimen NAM-NK Cells Elotuzumab (Myeloma) or Rituximab (NHL) Primary endpoint: Maximum tolerated dose of NAM-NK cells Secondary endpoints: Overall response, toxicity 28 ClinicalTrials.gov Identifier NCT
29 Phase I Study of NAM-NK: Patient Outcomes Preliminary Safety Results No cytokine release syndrome or neurotoxicity observed in the first patients treated (n=2) Expected short-term neutropenia and thrombocytopenia observed No dose limiting toxicity; no Grade 3 or Grade 4 adverse events Patient y/o patient with follicular lymphoma diagnosed in Oct 2012; Stage IVA Adenopathy in upper and lower abdomen; bone marrow involved Ongoing treatments since 2012; tumor continued to progress 29 Bachanova et al., AACR Advances in Malignant Lymphoma 2018.
30 Phase I Study of NAM-NK: Patient Outcomes Patient 002: Radiographic Complete Response PRE-TREATMENT POST-NK CELL TREATMENT Key findings: Symptomatic resolution of bulky inguinal lymphadenopathy Complete response by CT/PET scan Biopsy of residual mass showed no evidence of lymphoma Evidence of expansion of donor NK cells in peripheral blood Study continues to actively enroll patients with multiple myeloma and NHL 30 Bachanova et al., AACR Advances in Malignant Lymphoma 2018.
31 Corporate Information 31
32 Financial Snapshot Total cash position is $28.6 million as of June 30, 2018 Raised more than $135 million since inception 65 employees Supported by dedicated syndicate of investors, with largest position held by Novartis 32
33 Key Completed and Anticipated Milestones Nicord Received Orphan Drug Designation from FDA* Presented Phase 1/2 data at ASH and Tandem Initiated Phase 3 study in high-risk hematologic malignancies Initiated Phase 1/2 study in severe aplastic anemia 2019: Report topline severe aplastic anemia data 2H19: Complete enrollment in Phase 3 study in high-risk hematologic malignancies 1H20: Report topline Phase 3 data NAM-NK Phase 1 study Initiated study 2018: Present preliminary data 2019: Complete patient enrollment 2019: Present additional data 33 *Orphan drug designation in U.S. is for NiCord as a novel graft modality for enhancement of cell engraftment and immune reconstitution in patients receiving hematopoietic stem cell transplant.
34 Investment Highlights NiCord : Product candidate for bone marrow transplant with curative potential Proven, proprietary nicotinamide (NAM)-based cell expansion technology Wholly-owned clinical pipeline sets the stage for multiple milestones through 2020 Experienced executive team; recently established U.S. headquarters 34
35 Company Overview October
Company Overview. January 2019
Company Overview January 2019 1 Disclaimer This Presentation includes certain projections and forward-looking statements as of the date of this Presentation provided by Gamida Cell Ltd (the Company ).
More informationCompany Overview. Investor Presentation. August 2018
Company Overview Investor Presentation August 2018 1 Notice to Investors The sole purpose of this Presentation (this Presentation ) is to assist recipients in deciding whether to proceed with a further
More informationFebruary Company Overview. Curative Treatments for Cancer and Orphan Genetic Diseases
February 2017 Company Overview Curative Treatments for Cancer and Orphan Genetic Diseases Curative Treatments for Orphan Indications NiCord - a bone marrow transplantation treatment for patients with high
More informationNiCord Single Unit Expanded Umbilical Cord Blood Transplantation: Results of Phase I/II Trials
NiCord Single Unit Expanded Umbilical Cord Blood Transplantation: Results of Phase I/II Trials Mitchell E. Horwitz, MD Duke University Medical Center Duke Cancer Institute Adult Umbilical Cord Blood Transplantation
More informationThe National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient
1988 199 1992 1994 1996 1998 2 22 24 26 28 21 212 214 216 218 Adult Donors Cord Blood Units The National Donor Program Graft Sources for Hematopoietic Cell Transplantation Dennis L. Confer, MD Chief Medical
More informationActinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting
December 4, 2018 Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting - Key highlights include near universal engraftment
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationAnnual Results 2017 & Business Update 13 April 2018
Annual Results 2017 & Business Update 13 April 2018 1 Disclaimer These slides and the accompanying oral presentation contain forward-looking statements and information. Forward-looking statements are subject
More informationResults of Nicord Phase I II Trials and Plans for Phase III Trial
Results of Nicord Phase I II Trials and Plans for Phase III Trial Mitchell E. Horwitz, MD Duke Cancer Institute Duke University Medical Center June 10, 2016 Learning Objectives To provide an overview of
More informationQ4 Report Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Q4 Report 2018 Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation has been prepared by Calliditas Therapeutics AB
More informationWorld leader in navigated, non-invasive brain stimulation therapy and diagnosis
World leader in navigated, non-invasive brain stimulation therapy and diagnosis Martin Jamieson CEO & Chairman of the Board Nexstim Plc Mikko Karvinen CFO Nexstim Plc Corporate Presentation, BioTrinity,
More informationRapid and Robust CD4+ and CD8+ T-, NK-, BTitel and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood (NiCord) Transplantation
Rapid and Robust CD4+ and CD8+ T-, NK-, BTitel and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood (NiCord) Subtitel Transplantation Boelens/Nierkens lab Jaap Jan Boelens, Central Immune
More informationUMBILICAL CORD BLOOD STEM CELLS EXPANDED IN THE PRESENCE OF NICOTINAMIDE (NICORD) PROVIDE LONG TERM MULITI-LINEAGE ENGRAFTMENT
UMBILICAL CORD BLOOD STEM CELLS EXPANDED IN THE PRESENCE OF NICOTINAMIDE (NICORD) PROVIDE LONG TERM MULITI-LINEAGE ENGRAFTMENT Mitchell E. Horwitz, MD Duke University Medical Center Duke Cancer Institute
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationCompany presentation. Claudio Bordignon, Chairman and CEO. Jefferies Global Healthcare Conference New York, 7 June 2012
Company presentation Claudio Bordignon, Chairman and CEO Jefferies Global Healthcare Conference New York, 7 June 2012 Forward-looking statements The presentation contains certain forward-looking statements.
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationThe future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD
The future of HSCT John Barrett, MD, NHBLI, NIH Bethesda MD Transplants today Current approaches to improve SCT outcome Optimize stem cell dose and source BMT? PBSCT? Adjusting post transplant I/S to minimize
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_cell_transplantation_for_cll_and_sll 2/2001
More informationCell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Company Presentation June 2016
Cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders Company Presentation June 2016 Disclaimer These slides and the accompanying oral presentation contain
More informationZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015
ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015 1 Forward-looking Statements This presentation contains certain forward-looking information about ZIOPHARM
More informationProgrammed Cellular Immunotherapies
Better Cells For Better Therapies Programmed Cellular Immunotherapies Corporate Overview August 2017-1 - Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_waldenstrom_macroglobulinemia
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationMyeloid Differentiation Observed, Including Induction of CD38 in 85% of Evaluable Patients
December 10, 2017 Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients Clinical
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationBio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia
Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia Interim Data Update from Phase 2 Study Demonstrates Meaningful Clinical Improvement with
More informationInvestor presentation. Bioshares Biotech Summit July 2017
Investor presentation Bioshares Biotech Summit 2017 22 July 2017 1 Disclaimer Some of the information in this presentation may refer to Dimerix Limited ( Dimerix or the Company ) based on information available
More informationAsterias Biotherapeutics NYSE American: AST
Clinical-Stage Cell Therapy Programs Addressing Significant Unmet Medical Needs in Neurology and Oncology Asterias Biotherapeutics NYSE American: AST November 2017 Forward-Looking Statements Statements
More informationThird Quarter 2018 Financial Results. November 1, 2018
Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key
More informationValencia, 05/04/ #EBMT16
Transplantation of Ex vivo Expanded Umbilical Cord Blood (NiCord ) Results in Decreased Infection Burden and Hospital Length of Stay in the First 100 Days Sarah Anand, Samantha Thomas, Terry Hyslop, Kelly
More informationBone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa
Bone Marrow Transplantation in Myelodysplastic Syndromes An overview for the Myelodysplasia Support Group of Ottawa Objectives Provide brief review of marrow failure Re emphasize the importance of predictions
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationInvestment in MGC Pharmaceuticals
Investment in MGC Pharmaceuticals Investor Presentation May 2015 Disclaimer This presentation has been prepared by Erin Resources Limited ( Company ). It does not purport to contain all the information
More informationInvestor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Cell Transplantation for Hodgkin Lymphoma File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_cell_transplantation_for_hodgkin_lymphoma
More informationHaploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017
Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000
More informationSumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,
More informationStifel Healthcare Conference John Scarlett, M.D. Chief Executive Officer November 19, 2014
Stifel Healthcare Conference 2014 John Scarlett, M.D. Chief Executive Officer November 19, 2014 1 forward-looking statements Except for statements of historical fact, the statements during this presentation
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_ transplantation_for_primary_amyloidosis 2/2001 11/2018 11/2019 11/2018 Description
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationDelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75)
Equity Healthcare / Biotechnology Update (December 3, 2015) DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75) DelMar Pharmaceuticals, Inc. ( DelMar, OTCQX: DMPI) is a clinical stage biotechnology
More informationNOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017
NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A NKp46 C5aR Tumor antigen HALF-YEAR RESULTS KIR3DL2 MICA/B CD73 CD39 SEPTEMBER 18, 2017 Page 2 FORWARD LOOKING STATEMENT This document has been prepared by
More informationCorporate Presentation November Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation November 2015 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary
More informationOne Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases
One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationClinical Policy: Donor Lymphocyte Infusion Reference Number: CP.MP.101 Last Review Date: 11/17
Clinical Policy: Reference Number: CP.MP.101 Last Review Date: 11/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description
More informationClinical Policy: Donor Lymphocyte Infusion
Clinical Policy: Reference Number: PA.CP.MP.101 Effective Date: 01/18 Last Review Date: 11/16 Coding Implications Revision Log This policy describes the medical necessity requirements for a donor lymphocyte
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationHaplo vs Cord vs URD Debate
3rd Annual ASBMT Regional Conference for NPs, PAs and Fellows Haplo vs Cord vs URD Debate Claudio G. Brunstein Associate Professor University of Minnesota Medical School Take home message Finding a donor
More informationClinical Policy: Sargramostim (Leukine) Reference Number: CP.PHAR.295
Clinical Policy: (Leukine) Reference Number: CP.PHAR.295 Effective Date: 12/16 Last Review Date: 10/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationActinium Pharmaceuticals, Inc.
, Inc. Actimab-A MRD Consolidation Strategy in MRD+ AML July 10, 2018 1 Disclaimer and Safe Harbor Some of the information presented herein may contain projections or other forward-looking statements regarding
More informationPLEO-CMT Top-line Results. Presentation October 16, 2018
PLEO-CMT Top-line Results Presentation October 16, 2018 Disclaimer References herein to this presentation (the Presentation ) shall mean and include this document, any oral presentation accompanying this
More informationBobby W. Sandage, Jr., PhD President & Chief Executive Officer. Lazard Capital Markets 8 th Annual Healthcare Conference
Bobby W. Sandage, Jr., PhD President & Chief Executive Officer Lazard Capital Markets 8 th Annual Healthcare Conference Statements in this presentation that are not descriptions of historical facts are
More informationASH POSTER: LYMRIT UPDATE
ASH POSTER: LYMRIT 37-01 UPDATE DECEMBER 2018 EDUARDO BRAVO, CEO LISA ROJKJAER, MD, CMO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com IR contact: ir@nordicnanovector.com
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationFORM8-K HILLENBRAND,INC.
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): December18,2015
More informationSummary of Changes Page BMT CTN 1205 Protocol Amendment #4 (Version 5.0) Dated July 22, 2016
Page 1 of 8 Date: July 22, 2016 Summary of Changes Page BMT CTN 1205 Protocol #4 Dated July 22, 2016 The following changes, and the rationale for the changes, were made to the attached protocol in this
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationFIRSTQUARTER2018 RESULTSPRESENTATION
FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection
More informationNew Ideas. Better Medicines. Third Quarter Financial Results Conference Call
New Ideas. Better Medicines. Third Quarter 2018 Financial Results Conference Call Forward-Looking Statements 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties.
More informationAllogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:
Medical Policy Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Type: Medical Necessity and Investigational / Experimental Policy Specific Section:
More informationDonor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant
Last Review Status/Date: September 2014 Page: 1 of 8 Malignancies Treated with an Allogeneic Description Donor lymphocyte infusion (DLI), also called donor leukocyte or buffy-coat infusion is a type of
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More informationUPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma
UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Supported by a grant from Supported by a grant from UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Jonathan W.
More informationSunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights
Sunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights November 10, 2014 7:00 AM ET Announces Submission of Letter of Intent to File MAA for Vosaroxin in Relapsed or
More informationMerus. Corporate Presentation. November 15, 2018
Merus Corporate Presentation November 15, 2018 Disclaimer This presentation (including any oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of
More informationACACIA PHARMA ANNOUNCES ITS INTENTION TO LAUNCH AN INITIAL GLOBAL OFFERING AND TO LIST ITS SHARES ON EURONEXT BRUSSELS
This announcement is an advertisement for the purposes of the Prospectus Rules of the Financial Conduct Authority ( FCA ) and not a prospectus and not an offer of securities for sale in any jurisdiction,
More informationMANIFEST Phase 2 Enhancement / Expansion
MANIFEST Phase 2 Enhancement / Expansion Investor Conference Call Stellar Science, Breakthrough Medicine October 11, 2018 Forward-Looking Statements This presentation contains forward-looking statements
More informationa resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation
a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation This resource has been developed to help guide you regarding the appropriate timing and conditions for a referral
More informationInovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationRole of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT
Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT Stephen Spellman, MBS Director, Immunobiology and Observational Research Assistant Scientific Director CIBMTR,
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationVerona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva )
Press release 7 September 2017 Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva ) Achieved significant and clinically
More informationTamsulosin Hydrochloride 0.4 mg Capsule
Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationCONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints
CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH Potential
More informationAllogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD
Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state
More informationSummary of Changes BMT CTN 1101 Version 7.0 to 8.0 Dated: January 18, Original text: Changed to: Rationale
BMT CTN 1101 RIC ducb vs. Haplo Page 1 of 10 Date: January 20, 2017 Summary of Changes BMT CTN 1101 Version 7.0 to 8.0 Dated: January 18, 2017 A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC)
More informationMUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University
MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationPharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765
Contact: Ramses Erdtmann Vice President of Finance Phone: 408-215-3325 Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765 Company to Host
More informationBrisa Concessão Rodoviária. 1Q 2017 Traffic Update
Brisa Concessão Rodoviária 1Q 2017 Traffic Update 15 th May 2017 Disclaimer The information contained herein ( Information ) has been prepared by Brisa Concessão Rodoviária, S.A. ("BCR") and which, according
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationYescarta (axicabtagene ciloleucel)
Last Review Date: March 30, 2018 Effective Date: April 1, 2018 Number: MG.MM.PH.42 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider
More informationNOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ASX: NOX
Date: 14 August, 2018 Sydney, Australia ASX: NOX Noxopharm Limited NOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ABN 50 608 966 123 Registered Office and Operations Office: Suite 3,
More informationStem Cells And The Future of Regenerative Medicine. Dipnarine Maharaj, M. D., FACP
Stem Cells And The Future of Regenerative Medicine Dipnarine Maharaj, M. D., FACP The following potential conflict of interest relationships are germane to my presentation. Employment: South Florida Bone
More information